Jump Financial’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$464K Sell
77,930
-70,153
-47% -$333K ﹤0.01% 1734
2026
Q2
$656K Buy
148,083
+119,191
+413% +$509K 0.01% 1366
2026
Q1
$126K Buy
+28,892
New +$136K ﹤0.01% 1729
2024
Q4
– Sell
-73,697
Closed -$408K – 1715
2024
Q3
$408K Buy
+73,697
New +$418K 0.01% 1185
2023
Q4
– Sell
-43,404
Closed -$240K – 1863
2023
Q3
$240K Buy
+43,404
New +$348K 0.01% 1423
2023
Q2
– Sell
-99,089
Closed -$911K – 1861
2023
Q1
$911K Buy
99,089
+26,479
+36% +$285K 0.04% 635
2022
Q4
$741K Buy
+72,610
New +$976K 0.04% 614
2022
Q2
– Sell
-34,854
Closed -$376K – 1686
2022
Q1
$376K Buy
+34,854
New +$471K 0.02% 950

Other funds holding CTKB

Jump Financial's CTKB Position: Q3 2026 in Review

Jump Financial reduced its Cytek Biosciences (CTKB) stake by 47% in Q3 2026, selling an estimated $333K and leaving 77,930 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Jump Financial first reported a position in CTKB in Q1 2022 and has held it in 8 quarters since. The position peaked at $911K in Q1 2023. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Jump Financial held 77,930 shares of Cytek Biosciences worth $464K as of Q3 2026.
  • Jump Financial sold 70,153 Cytek Biosciences shares in Q3 2026, an estimated $333K.
  • Cytek Biosciences made up ﹤0.01% of Jump Financial's portfolio in Q3 2026, its #1734 holding.
  • Jump Financial first reported a position in Cytek Biosciences in Q1 2022 and has held it in 8 quarters since.
  • Jump Financial's Cytek Biosciences position peaked at $911K in Q1 2023.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Jump Financial's 13F filing for Q3 2026, filed 13 Nov 2026.